Overview
Portfolio
More
Tullisfunds
North Palm Beach, United States
Invests in repeatable, scalable commercial healthcare companies, focusing on North American market.
Portfolio
17+
Employees
15+
Founded
1986
AUM
≈ $21.4M
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
North America
Fund details
Funds
Tullis Growth Fund
$21.4M
Sources
Tullisfunds
Invests in repeatable, scalable commercial healthcare companies, focusing on North American market.
Portfolio
17+
Employees
15+
Founded
1986
AUM
≈ $21.4M
Funds
Tullis Growth Fund · $21.4M
Stages
No stages listed
Industries
No industries listedGeographic scope
North America
Sources
Showing 10 of 10 matched portfolio companies
Cohere is an all-in-one platform that integrates essential tools for coaches and service providers, including course builders, scheduling, payment processing, and community management, all within a single interface. It eliminates the need for multiple software solutions, saving users over $1,700 annually and freeing up significant time to focus on business growth and client engagement.
electroCore develops non-invasive vagus nerve stimulation (nVNS) technology to provide safe and clinically validated treatments for patients suffering from chronic pain and related conditions. By utilizing nVNS, the company aims to enhance treatment options and improve the quality of life for individuals dissatisfied with existing therapies.
HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.
The startup operates a zero-knowledge oracle network for Ethereum, utilizing zero-knowledge proofs to facilitate secure off-chain computation for tasks such as automation and machine learning inference. This technology enhances the functionality and reliability of smart contracts, enabling developers to create more sophisticated decentralized applications without compromising on trust or security.
15+
500+Approximate amount of employees
Funding: $23.0M
Rough estimate of the amount of funding raised
Funding: $23.0M
Rough estimate of the amount of funding raised
The startup develops therapeutic drugs that leverage the ubiquitin-proteasome system to regulate protein levels in the body. This approach targets diseases such as cancer by utilizing natural biological processes for protein degradation.
Funding: $48.4M
Rough estimate of the amount of funding raised
Funding: $48.4M
Rough estimate of the amount of funding raised
Pulse is an AI‑native Feedback Intelligence operating system for enterprises that consolidates customer signals from support tickets, CRM, calls, app reviews, and other channels into a unified repository. Its AI agents deduplicate, detect themes, and prioritize insights by measurable business impact, then automatically route actionable items to tools like Jira, Linear, Notion, and Slack, enabling product, CX, and operations teams to make data‑driven decisions quickly.
Funding: $1.4M
Rough estimate of the amount of funding raised
Funding: $1.4M
Rough estimate of the amount of funding raised
RESPIRA is an automated invasive ventilator designed for emergency and intensive care, enabling precise control and monitoring of key respiratory parameters. It addresses the critical need for reliable ventilation in health emergencies by offering multiple ventilation modes and real-time alerts for deviations in breathing metrics.
The startup offers an AI-driven platform that connects businesses with suitable partners throughout their innovation journey. By leveraging machine learning algorithms, it enhances strategic collaboration, enabling companies to identify and engage with startups that align with their specific needs.
TR Corporation develops AI-driven smart healthcare devices and electronic products in collaboration with medical professionals and researchers. Their technology addresses the need for advanced health monitoring solutions, enhancing patient care and promoting healthier lifestyles.
This company develops a therapeutic platform designed to improve outcomes for patients with solid tumors, specifically targeting liver and pancreatic cancers. Their approach integrates novel drug delivery technology with immunotherapies to overcome intratumoral pressure and the immunosuppressive tumor microenvironment. The platform aims to enhance the efficacy of standard-of-care therapies and investigational immunotherapies in these difficult-to-treat cancers.
Showing 7 of 7 unmatched portfolio companies